Anterix (NASDAQ:ATEX – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.27), reports. The firm had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.52 million. Anterix had a negative return on equity of 18.42% and a negative net margin of 217.80%.
Anterix Stock Up 17.0 %
NASDAQ ATEX opened at $36.29 on Friday. The company has a fifty day simple moving average of $32.13 and a 200 day simple moving average of $33.08. Anterix has a 1 year low of $27.20 and a 1 year high of $40.45.
Insider Buying and Selling
In related news, CFO Timothy Gray sold 16,667 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $31.91, for a total transaction of $531,843.97. Following the completion of the sale, the chief financial officer now directly owns 90,475 shares of the company’s stock, valued at approximately $2,887,057.25. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 31.71% of the stock is owned by insiders.
Institutional Trading of Anterix
Anterix Company Profile
Anterix Inc operates as a wireless communications company. The company focuses on commercializing its spectrum assets to enable the targeted utility and critical infrastructure customers to deploy private broadband networks and innovative broadband solutions. It holds licensed spectrum in the 900 MHz band with coverage throughout the United States, Alaska, Hawaii, and Puerto Rico.
Further Reading
- Five stocks we like better than Anterix
- How to invest in marijuana stocks in 7 stepsĀ
- Albemarle Stock: Strong Fundamentals vs. Lithium Volatility
- Consumer Staples Stocks, Explained
- MongoDB Stock: Analysts Recommend Buying the Dip
- What Are the FAANG Stocks and Are They Good Investments?
- UniFirst Stock: Value-Building Sends a Signal to the Market
Receive News & Ratings for Anterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anterix and related companies with MarketBeat.com's FREE daily email newsletter.